Aminoglycoside-free interventional antibiotic management in patients undergoing haemopoietic stem cell transplantation

The position of aminoglycosides within interventional antibiosis in the early phase after stem cell transplantation has not been fully clarified so far although their use can induce serious renal impairment. To investigate this question early-infection data from 152 patients undergoing 195 allogeneic and autologous stem cell transplantations were investigated. Prophylaxis and treatment of infections followed international standards; however, aminoglycosides were omitted to avoid additional risks such as ototoxicity and nephrotoxicity and increased selection of resistant pathogens. Costs were another aspect. The overall-incidence of infections was 78% (152/195) and 67 patients showed more than one episode of infection. Fever of unknown origin and bacteriaemia/septicaemia dominated the spectrum of infections. The overall-response to interventional regimen consisting of β-lactam or carbapenem plus glycopeptides was 48%. Aminoglycosides were given in three patients in the late course of disease. Overall mortality was 15/195 (7.7%) and clearly related to infection in nine cases mostly due to mould infection. A comparison with previous published literature showed no hint for inferiority of ‘aminoglycoside-free’ antibiotic management in stem cell transplant patients. In conclusion, the present analysis supports the policy to omit aminoglycosides in the therapy of early infections in patients undergoing stem cell transplantation to avoid additional toxicity.

[1]  M. Falagas,et al.  Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. , 2005, Mayo Clinic proceedings.

[2]  H. Einsele,et al.  Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Maris,et al.  Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. , 2004, Blood.

[4]  R. Storb,et al.  Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review , 2004, Springer Seminars in Immunopathology.

[5]  O. Sezer,et al.  Antimicrobial therapy of unexplained fever in neutropenic patients , 2003, Annals of Hematology.

[6]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[7]  D. Herrington,et al.  Ciprofloxacin plus Piperacillin Compared with Tobramycin plus Piperacillin as Empirical Therapy in Febrile Neutropenic Patients , 2002, Annals of Internal Medicine.

[8]  F. Mandelli,et al.  A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Wingard,et al.  Infections following hematopoietic stem cell transplantation. , 2001, Infectious disease clinics of North America.

[10]  T. Nakashima,et al.  Vestibular and cochlear toxicity of aminoglycosides--a review. , 2000, Acta oto-laryngologica.

[11]  M. Offidani,et al.  Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF , 1999, Bone Marrow Transplantation.

[12]  P. Tulkens,et al.  Aminoglycosides: Activity and Resistance , 1999, Antimicrobial Agents and Chemotherapy.

[13]  N. Kröger,et al.  Early infections in patients undergoing bone marrow or blood stem cell transplantation – a 7 year single centre investigation of 409 cases , 1999, Bone Marrow Transplantation.

[14]  S. Zinner.  Relevant aspects in the Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1998, International journal of hematology.

[15]  A. Vekhoff,et al.  Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. , 1998, The Journal of antimicrobial chemotherapy.

[16]  H. Senn,et al.  Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients , 1998, Supportive Care in Cancer.

[17]  C. Huber,et al.  Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation , 1997, Bone Marrow Transplantation.

[18]  R. Feld,et al.  Ceftazidime Compared with Piperacillin and Tobramycin for the Empiric Treatment of Fever in Neutropenic Patients with Cancer: A Multicenter Randomized Trial , 1994, Annals of Internal Medicine.

[19]  C. Bokemeyer,et al.  Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC). , 1993, European urology.